Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

Validating Integrative Multi-omics Approaches in Metabolic Syndrome-related Diseases

NCT07248371 · tracked via the Priya Life Science Taiwan tracker
Phase
Observational
Started
2025-06-09
Last updated
2025-11-25

Condition(s) studied

Metabolic Syndrome (MetS)Obesity & OverweightCardiovascular Diseases (CVD)Chronic Kidney DiseaseNonalcoholic Fatty Liver DiseaseHealthy

Investigational drug(s) / intervention(s)

No intervention

No intervention: no intervention

Study summary

This study aims to validate integrative multi-omics approaches for understanding complications related to metabolic syndrome. By combining genetic, transcriptomic, metabolomic, and microbiome data from participants with and without metabolic syndrome, the research seeks to determine which biological factors predict disease progression and how these insights can inform precision prevention and treatment strategies for metabolic disorders.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Individuals (male or female) aged 20 years or older * Willing and able to provide written informed consent to participate in the study Exclusion Criteria: * Pregnant or breastfeeding women * Patients with end-stage renal disease receiving hemodialysis or peritoneal dialysis * Individuals currently undergoing active cancer treatment * Recipients of any organ transplantation * Patients diagnosed with dementia

Primary outcome measure(s)

  • Identification and validation of multi-omics biomarkers associated with metabolic syndrome and its complications — 5 years
    Comprehensive integration of genomic, transcriptomic, metabolomic, and microbiome datasets to identify molecular signatures predictive of metabolic syndrome progression and related complications (e.g., cardiovascular disease, chronic kidney disease, fatty liver).

Trial sites (1)

FacilityCityRegionStatus
Chang Gung Memorial Hospitals, Linkou Taoyuan Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07248371 on ClinicalTrials.gov ↗ ← All trials in Taiwan